+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Global Precision Medicine Market

  • ID: 4434677
  • Report
  • Region: Global
  • 125 pages
  • Mordor Intelligence
until Dec 31st 2019
1 of 5


  • Eagle Genomics Ltd.
  • Ferrer Incode
  • Intomics
  • Medtronic
  • Nanostring Technologies
  • Novartis
  • MORE
Precision Medicine Market

Precision medicine is an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person. It is a combination of molecular biology techniques and systems biology. Precision medicine is one of the greatest opportunities for new medical breakthroughs.

Precision medicine will enable a new era of medicine in which researchers, providers, and patients work together to develop individualized care. Oncology is the initial area of focus for precision medicine, as cancer is one of the leading causes of death worldwide, and its incidence is increasing as the population ages. The patients diagnosed with cancer in 2004 would have had only a 10% chance of obtaining the right treatment for the disease as compared to a 70-80% chance of getting the right treatment today. Many genetically targeted therapies are currently available to cancer patients, and many more are expected to become available in the near future. A large amount of research and development has been undertaken for the development of precise drugs, targeted therapeutics, and laboratory tests for various disease conditions. In FY2015, the NIH invested nearly USD 30.3 billion in medical research that allows investigators to come up with new ideas that can help change the world.

Global Precision Medicine Market- Market Dynamics

There are several driving and restraining factors for the global precision medicine market. Some of these are listed below.


There are large, established online forums that help clinicians collaborate with one another and share information, which will help in the diagnosis and treatment of patients in a better manner. This is a key driving factor for the precision medicine market. Some other driving factors for this market are:
Incidence Of Online Collaborative Forums
Increasing Efforts To Characterize Genes
Advancement In Cancer Biology


Perils Of Data Sharing
Shift From Treatment Based To Preventive Healthcare
Declining Trends In The Fda Pharmacotherapy Approval Rate

The segmentation of the market for precision medicine is done based on technology (big data analytics, bioinformatics, gene sequencing, drug discovery, companion diagnostics and others), and application (oncology, CNS, immunology, respiratory medicine, infections and others).

The drug discovery market holds the largest share, followed by gene sequencing and companion diagnostics. In August 2014, UK Prime Minister David Cameron announced EUR 300 million funding for a four-year project to map 100,000 people’s genomes by 2017. Big data analytics is expected to grow at the highest CAGR during the forecast period.

Based on geography, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The North American market dominates the global precision medicine market with the USA contributing the highest share of revenue, followed by Europe. The spread of analytics and awareness of its potential are increasing at a rapid rate in Europe. The market in the APAC region is growing at a fast pace. This can be attributed to the developments in China and India.

Many players in this market are trying to expand their product portfolio in order to top the global market. While some companies are entering the market by acquisitions, top companies are expanding their growth in this market by acquiring other companies. A few companies have adopted product innovation and new product launches as their key business strategy to ensure their dominance in this market. The major French drug company Sanofi has recently announced that their drug Praluent, which can significantly reduce low-density lipoprotein cholesterol, has received approval from the European Commission for treating adult patients suffering from hypercholesterolemia and LDL cholesterol.

Some of the key players in the market are:

Ferrer In
Nanostring Technologies
Silicon Biosystems
Tepnel Pharma Services

What the Report Offers
Market analysis for the precision medicine market, with region-specific assessments and competition analysis on the global and regional scale.
Market definition along with the identification of key drivers and restraints.
Identification of factors instrumental in changing the market scenario, rising prospective opportunities, and identification of key companies that can influence this market on a global and regional scale.
Extensively researched competitive landscape section with profiles of major companies along with their market share.
Identification and analysis of the macro and micro factors that affect the precision medicine market on both global and regional scale.
A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.
A wide-ranging knowledge and insights about the major players in this industry and the key strategies adopted by them to sustain and grow in the studied market.
Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped.
Note: Product cover images may vary from those shown
2 of 5


  • Eagle Genomics Ltd.
  • Ferrer Incode
  • Intomics
  • Medtronic
  • Nanostring Technologies
  • Novartis
  • MORE
1. Introduction
1.1 Market Definition

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview
5.1 Current Market Scenario
5.2 Market Overview
5.3 Porter’s Five Force Analysis
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Degree of Competition
5.3.4 Threat of Substitution
5.3.5 Threat of New Entrants

6. Drivers, Restraints, Opportunities, and Challenges (Droc) Analysis
6.1 Market Drivers
6.1.1 Incidence of Online Collaborative Forums
6.1.2 Increasing Efforts to Characterize Genes
6.1.3 Advancement in Cancer Biology
6.2 Market Restraints
6.2.1 Perils of Data Sharing
6.2.2 Shift from Treatment Based to Preventive Healthcare
6.2.3 Declining Trends in the Fda Pharmacotherapy Approval Rate
6.3 Market Opportunities
6.4 Market Challenges

7. Market Segmentation
7.1 by Technology
7.1.1 Big Data Analytics
7.1.2 Bioinformatics
7.1.3 Gene Sequencing
7.1.4 Drug Discovery
7.1.5 Companion Diagnostics
7.1.6 Others
7.2 by Application
7.2.1 Oncology
7.2.2 Immunology
7.2.3 Cns
7.2.4 Respiratory
7.2.5 Others
7.3 by Geography
7.3.1 North America United States Canada Mexico
7.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
7.3.3 Asia-Pacific Japan China India South Korea Australia Others
7.3.4 Middle East & Africa Gcc South Africa Rest of Middle East & Africa
7.3.5 South America Brazil Argentina Others

8. Competitive Landscape
8.1 Mergers and Acquisition Analysis
8.2 Agreements, Collaborations and Partnerships
8.3 New Product Launches

9. Company Profiles
9.1 Biocrates Life Sciences Ag
9.2 Nanostring Technologies
9.3 Intomics
9.4 Ferrer Incode
9.5 Pfizer
9.6 Eagle Genomics Ltd.
9.7 Teva Pharmaceuticals
9.8 Laboratory Corporation of America Holdings
9.9 Medtronic
9.10 Novartis
9.11 Qiagen
9.12 Quest Diagnostics
9.13 Roche Holding Ag

10. Future Outlook of the Market
Note: Product cover images may vary from those shown
3 of 5


4 of 5
  • Biocrates Life Sciences Ag
  • Nanostring Technologies
  • Intomics
  • Ferrer Incode
  • Pfizer
  • Eagle Genomics Ltd.
  • Teva Pharmaceuticals
  • Laboratory Corporation of America Holdings
  • Medtronic
  • Novartis
  • Qiagen
  • Quest Diagnostics
  • Roche Holding Ag
Note: Product cover images may vary from those shown
5 of 5